Avidity Biosciences Inc (RNAM) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Feb 18Feb 23Feb 26Mar 3Mar 10Mar 13Mar 18Mar 23

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.4x

Market Cap

$10.03B

MomentumView details →

1D Return

+0.05%

YTD Return

—

RSI (14)

59.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.4x

Market Cap

$10.03B

RSI (14)

59.0

MomentumView details →

1D Return

+0.05%

YTD Return

—

ProfitabilityView details →

Gross Margin

77.87%

Net Margin

−3650.39%

EBITDA Margin

−3955.17%

ROE (TTM)

−40.54%

ROA (TTM)

−34.96%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

+72.11%

EPS YoY

−71.03%

FCF YoY

—

Revenue CAGR 3Y

+26.69%

EPS CAGR 3Y

−71.97%

EBITDA YoY

−97.20%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

9.20x

Quick Ratio

9.20x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

18.75M

Net Income (TTM)

−684.63M

Op. CF (TTM)

−650.44M

Latest newsMore news →

Novartis AG reported that its experimental drug del-brax, acquired through the Avidity Biosciences deal, showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy.73d ago

Novartis acquired Avidity as part of a $12 billion takeover.85d ago

Similar companies

Cytokinetics, IncorporatedCYTK Abivax S.A.ABVX Praxis Precision Medicines, Inc.PRAX Apogee Therapeutics, Inc.APGE Kymera Therapeutics, Inc.KYMR Ascletis Pharma Inc.01672.HK Find similar companies →

Latest newsMore news →

Novartis AG reported that its experimental drug del-brax, acquired through the Avidity Biosciences deal, showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy.73d ago Novartis acquired Avidity as part of a $12 billion takeover.85d ago